{"id":"NCT00307801","sponsor":"Bayer","briefTitle":"Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding","officialTitle":"A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, 7 Cycle Duration (196 Days), Phase 3 Study of Oral Estradiol Valerate/Dienogest Tablets for the Treatment of Dysfunctional Uterine Bleeding.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-02","primaryCompletion":"2008-05","completion":"2008-05","firstPosted":"2006-03-28","resultsPosted":"2011-07-29","lastUpdate":"2014-12-30"},"enrollment":231,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Metrorrhagia"],"interventions":[{"type":"DRUG","name":"Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether the study drug is safe and effective in the treatment of dysfunctional uterine bleeding.","primaryOutcome":{"measure":"Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms","timeFrame":"Efficacy phase was defined as a 90-day period under treatment. For patients who completed up to day 6 of treatment cycle 7, the efficacy phase started on the first day of treatment cycle 4, and continued through day 6 of treatment cycle 7","effectByArm":[{"arm":"Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027)","deltaMin":0.295,"sd":null},{"arm":"Placebo","deltaMin":0.012,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":36,"countries":["Australia","Czechia","Finland","Germany","Hungary","Netherlands","Poland","Sweden","Ukraine","United Kingdom"]},"refs":{"pmids":["22240178","21774563","21784734","22927764","23439617"],"seeAlso":["http://www.clinicaltrialsregister.eu/"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":145},"commonTop":["Headache","Nasopharyngitis","Serum ferritin decreased","Metrorrhagia","Breast pain"]}}